Kite scores a landmark win with promising 6-month lymphoma data for lead CAR-T
Kite Pharma’s closely-watched lead CAR-T turned in positive six-month results for aggressive non-Hodgkin lymphoma, hitting a key goal as the biotech rolls up to the FDA with its application for marketing approval.
A group of skeptics had lashed the company after its three-month results, which demonstrated a cluster of relapses and a sharp drop in objective response rates and complete responses for axicabtagene ciloleucel (KTE-C19). But CEO Arie Belldegrun told me last fall that investigators believed that the six-month results would show that the efficacy plateaued, demonstrating its durability.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.